Top

Published in:

01-06-2011

Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring

Author: Steven Trifilio

Published in: Current Fungal Infection Reports | Issue 2/2011

Abstract

The prevention and treatment of invasive fungal infections can be compromised by antifungal agents that display unpredictable pharmacokinetics and significant drug interactions and which demonstrate a strong relationship between drug exposure and efficacy and toxicity. Clinical studies have shown that maintaining antifungal drug levels within a targeted range decreases the risk for treatment failure and drug toxicity and thus have established a role for therapeutic drug monitoring with the use of various agents. Evidence from experimental and clinical studies supporting the role of therapeutic drug monitoring and practical applications for attaining targeted levels are reviewed.

Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.PubMedCrossRef

Person AK, Kontoyiannis DP, Alexander BD, et al. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am. 2010;24(2):439–59.PubMedCrossRef

Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol. 2010;22(2):138–42.PubMedCrossRef

Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.PubMedCrossRef

Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493–9.PubMedCrossRef

Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16(5):445–52.PubMedCrossRef

• Kontoyiannis DP. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: The unfinished tale of imperfect success. Bone Marrow Transplant. 2011;46(2):165–73. This article presents an insightful perspective on antifungal prophylaxis based upon risk stratification. Established antifungal prophylaxis guidelines, limitations, newly identified metabolic and genetic risk factors, and future directions are discussed. PubMedCrossRef

Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia. 2009;168(6):299–311.PubMedCrossRef

Decosterd LA, Rochat B, Pesse B, et al. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother. 2010;54(12):5303–15.PubMedCrossRef

10.

Law D, Moore CB, Denning DW. Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays. J Antimicrob Chemother. 1999;44(4):577–8.PubMedCrossRef

11.

Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5.PubMedCrossRef

12.

Hope WW, Petraitis V, Petraitiene R, et al. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1- >3) β-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother. 2010;54(11):4879–86.PubMedCrossRef

13.

• Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9. Collectively, references [10] through [13] identify delay in antifungal drug therapy as a risk factor for treatment failure and increased mortality. PubMedCrossRef

14.

Miyakis S, van Hal SJ, Solvag CJ, et al. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. Ther Drug Monit. 2010;32(5):661–5.PubMedCrossRef

15.

Andes D, Safdar N, Marchillo K, et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother. 2006;50(2):674–84.PubMedCrossRef

16.

Lewis RE, Liao G, Hou J, et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006;50(2):674–84.CrossRef

17.

Lestner JM, Howard SJ, Goodwin J, et al. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2010;54(8):3432–41.PubMedCrossRef

18.

Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2010;54(3):1298–304.PubMedCrossRef

19.

Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289–97.PubMedCrossRef

20.

Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001;322(7286):579–82.PubMedCrossRef

21.

Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333–42.PubMed

22.

Vermes A. An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. Chemotherapy. 2003;49(1–2):17–23.PubMedCrossRef

23.

Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother. 2000;44:938–42.PubMedCrossRef

24.

Stamm A, Diasio A, Dismukes R, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83:236–42.PubMedCrossRef

25.

Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992;15(6):1003–18.PubMedCrossRef

26.

Hope W, Warn PA, Sharp A, et al. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother. 2006;50(11):3680–8.PubMedCrossRef

27.

Perfect J, Dismukes W, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322.PubMedCrossRef

28.

Pappas G, Kauffman C, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRef

29.

Pasqualotto A, Howard S, Moore C, Denning DW. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007;59:791–3.PubMedCrossRef

30.

Manjunath P, Pai M, Bruce H, et al. Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. Antimicrob Agents Chemother. 2010;54(3):1237–41.CrossRef

31.

Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother. 1999;43(9):2116–20.PubMed

32.

Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47(10):3165–9.PubMedCrossRef

33.

Andes D, Marchillo K, Conklin R, Krishna G, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis D. Antimicrob Agents Chemother. 2004;48(1):137–42.PubMedCrossRef

34.

Bartel A, Phatak A, Horn K, et al. Drug interactions involving antifungal drugs: time course and clinical significance. Curr Fungal Infect Rep. 2010;4:103–10.CrossRef

35.

Te Loo DM. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukemia [abstract]. American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract 10049.

36.

Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol. 2001;18(8):543–6.PubMedCrossRef

37.

Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer. 2009;52(2):298–300.PubMedCrossRef

38.

Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract. 2009;15(3):175–82.PubMedCrossRef

39.

Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol. 2009;31(4):292–5.PubMedCrossRef

40.

Yamazaki H, Nakamoto M, Shimizu M, et al. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol. 2010;69(6):593–7.PubMedCrossRef

41.

Pinto A, Chan RC. Lack of allergic cross-reactivity between fluconazole and voriconazole. Antimicrob Agents Chemother. 2009;53(4):1715–6.PubMedCrossRef

42.

Spellberg B, Rieg G, Bayer A, et al. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis. 2003;36:1091–3.PubMedCrossRef

43.

Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on antifungal susceptibility testing of the National Committee for clinical laboratory standards. Clin Infect Dis. 1997;24(2):235–47.PubMedCrossRef

44.

Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51(1):35–9.PubMedCrossRef

45.

Baddley J, Patel M, Manjunath S, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52(9):3022–8.PubMedCrossRef

46.

Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007;16(8):919–27.PubMedCrossRef

47.

Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37:778–84.PubMed

48.

Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201–6.PubMedCrossRef

49.

Freeman J, Heshmati A, Holland D, et al. Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation. J Antimicrob Chemother. 2007;60(4):908–9.PubMedCrossRef

50.

Glasmacher A, Hahn C, Molitor E, et al. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42(11–12):591–600.PubMedCrossRef

51.

Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998;35(6):461–73.PubMedCrossRef

52.

Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56 Suppl 1:i17–22.PubMedCrossRef

53.

Hagihara M, Kasai H, Umemura T, et al. Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units. J Infect Chemother. 2010 Aug 27 (Epub ahead of print).

54.

Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21(24):4615–26.PubMedCrossRef

55.

Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.PubMedCrossRef

56.

Denning DW, Tucker RM, Hanson LH, et al. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989;86:791–800.PubMedCrossRef

57.

Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990;112:108–12.PubMed

58.

Denning DW, Tucker RM, Hanson LH, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989;149:2301–8.PubMedCrossRef

59.

• Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis. 2009;49(6):928–30. This is the largest and most comprehensive analysis of the relationship between itraconazole drug exposure and adverse events. PubMedCrossRef

60.

Lestner JM, Denning DW. Tremor: a newly described adverse event with long-term itraconazole therapy. J Neurol Neurosurg Psychiatry. 2010;81:327–9.PubMedCrossRef

61.

Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.PubMedCrossRef

62.

Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–15.PubMedCrossRef

63.

Myrianthefs P, Markantonis SL, Evaggelopoulou P, et al. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents. 2010;35(5):468–72.PubMedCrossRef

64.

Han K, Capitano B, Bies R, Potoski BA, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 2010;54(10):4424–31.PubMedCrossRef

65.

Johnson HJ, Han K, Capitano B, et al. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother. 2010;54(2):852–9.PubMedCrossRef

66.

Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109(8):1532–5.PubMedCrossRef

67.

• Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27–36. This recent retrospective analysis of voriconazole trough concentrations in 46 children observed large interpatient variability and (similar to results reported in adults) an association between a voriconazole trough >1 μg/mL and improved survival, supporting a role for TDM. PubMedCrossRef

68.

Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23.PubMedCrossRef

69.

Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54(7):1050–2.PubMed

70.

Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother. 2010;54(8):3225–32.PubMedCrossRef

71.

Background Document for the Antiviral Drug Products Advisory Committee Meeting. October 4, 2001. Available at www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-voriconazole.htm.

72.

Denning DW, Ribaud P, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–71.PubMedCrossRef

73.

Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50(4):1570–2.PubMedCrossRef

74.

• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11. This is the first and only study to date in adults that has observed a significant correlation between prospectively targeted voriconazole plasma concentrations above 1 μg/mL and improved patient outcomes. Correction of suboptimal voriconazole levels in treatment failures was associated with improved outcomes in all patients. PubMedCrossRef

75.

Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5):451–6.PubMedCrossRef

76.

• Wingard JR, Carter SL, Walsh TJ, et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood. 2010;116(24):5111–8. The results of this large, randomized, multi-institutional trial in HSCT recipients found fluconazole to be equally efficacious to voriconazole for the prevention of IFI, implying that broadened antifungal prophylaxis may not be of additional benefit. PubMedCrossRef

77.

Pongas GN, Lewis RE, Samonis G, et al. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect. 2009;15 Suppl 5:93–7.PubMedCrossRef

78.

Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235–43.PubMedCrossRef

79.

Gorski E, Esterly J, Postelnick M, et al. An evaluation of hepatotoxicity with off-label oral treatment doses of voriconazole for invasive fungal infections. Antimicrob Agents Chemother. 2011;55(1):184–9.PubMedCrossRef

80.

Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136(45–46):739–42.PubMed

81.

Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47(1):e7–10.PubMedCrossRef

82.

Trifilio SM, Yarnold PR, Scheetz MH, et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53(5):1793–6.PubMedCrossRef

83.

Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006;50(5):1881–3.PubMedCrossRef

84.

Courtney R, Wexler D, Radwanski E, Lim J, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218–22.PubMedCrossRef

85.

Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48(3):804–8.PubMedCrossRef

86.

Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44(2):211–20.PubMedCrossRef

87.

Ullmann A, Cornely O, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658–66.PubMedCrossRef

88.

Li Y, Theuretzbacher C, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379–96.PubMedCrossRef

89.

Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126–33.PubMedCrossRef

90.

Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2–12.PubMedCrossRef

91.

Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother. 2011;55(3):1308–11.PubMedCrossRef

92.

Oliver A, Cornely O, Maertens J, Drew J, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.CrossRef

93.

Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.PubMedCrossRef

94.

Thompson G, Rinaldi M, Pennick G, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother. 2009;53(5):2223–4.PubMedCrossRef

95.

Migoya EM, Mistry GC, Stone JA, et al. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol. 2011;51(2):202–11.PubMedCrossRef

96.

Lewis RE, Albert ND, Kontoyiannis DP, et al. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother. 2008;61(5):1140–4.PubMedCrossRef

97.

Horn DL, Ostrosky-Zeichner L, Morris MI, et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis. 2010;29(2):223–9.PubMedCrossRef

98.

Hope W, Seibel N, Schwartz C, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51(10):3714–9.PubMedCrossRef

99.

Neely M, Jafri H, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009;53(4):1450–6.PubMedCrossRef

Title: Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring
Author: Steven Trifilio
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Fungal Infection Reports / Issue 2/2011
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-011-0050-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Antifungal Dosing in Obesity: A Review of the Literature

Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients

Antifungal Therapy in Pediatric Patients

Optimizing Amphotericin B Therapy for Cryptococcal Meningitis

Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans

Antifungal Dosing in Dialysis and Continuous Renal Replacement Therapy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials